A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

Documenti analoghi

• Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer
  di: Jieran Long, et al.
  Pubblicazione: (2024)
• Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
  di: Li Li, et al.
  Pubblicazione: (2024)
• Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
  di: Mingyue Cai, et al.
  Pubblicazione: (2024)
• Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
  di: Xiaofen Li, et al.
  Pubblicazione: (2024)
• Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
  di: Shuling Shi, et al.
  Pubblicazione: (2024)